New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
Immunotherapy that inhibits the interaction between programmed death ligand 1 (PD-L1), present on the surface of tumor or antigen-presenting cells, and programmed death 1 (PD-1), present on the surface of activated lymphocytes, is generating much excitement and enthusiasm. Although considerable know...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-04-01
|
| Series: | European Journal of Inflammation |
| Online Access: | https://doi.org/10.1177/1721727X15626423 |